Abraxis Research is driving the discovery, research, and development, from bench-to-clinic, of new products and innovative core technologies that improve the lives of seriously ill patients. A key priority is to leverage and exploit the potential for Abraxis’ nanoparticle albumin-bound or nab™ technology, while continuing the discovery and development of new products. Abraxis relies on its rich research heritage with extensive multifunctional chemistry capabilities, seasoned clinical development and regulatory experts to accelerate clinical proofs-of-principle leading to next-generation technology discoveries.

Protosphere™: An Abraxis Advance in Nanoparticle Technology
Abraxis has developed a revolutionary new technology of creating protein nanoparticles that are suitable for in vivo delivery of a potentially broad range of drugs. Called Protosphere™, this technology offers the ability to convert insoluble or poorly soluble drugs into nanoparticles allowing them to become soluble and easier to deliver. Insoluble or poorly soluble drugs are combined with biocompatible proteins to make them soluble, avoiding the need for toxic chemicals often used as solvents. Removing the chemicals eliminates solvent-related toxicities and other dose-limiting complications to improve safety and efficacy. Protosphere™ provides a broad variety of routes of administration including intravenous, intra-arterial, inhalational, topical, and oral.